Improved robotic surgery for advanced prostate cancer
Improved Robotic-Assisted Radical Prostatectomy for Locally Advanced Prostate Cancer: Bladder Suspension and Preliminary Outcomes
This study tests a new robotic surgery technique for advanced prostate cancer to see if it helps improve recovery and urinary control compared to standard methods.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 300 (estimated) |
| Sex | Male |
| Sponsor | First Affiliated Hospital of Fujian Medical University Academic / other |
| Locations | 1 site (Fuzhou, Fujian) |
| Trial ID | NCT06977906 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates an enhanced technique for robotic-assisted radical prostatectomy aimed at treating locally advanced prostate cancer. The study focuses on the impact of preserving the anterior peritoneum of the bladder on postoperative outcomes, particularly bladder descent and urinary control recovery. It compares this modified approach with traditional surgical methods through a prospective, single-center design, assessing oncological outcomes, functional recovery, and complication rates. The findings aim to provide new insights and technical support for managing postoperative urinary incontinence.
Who should consider this trial
Good fit: Ideal candidates include men with high-risk prostate cancer confirmed by biopsy and imaging, who are in good general health and can undergo robotic-assisted surgery.
Not a fit: Patients with surgical contraindications or those who refuse enhanced imaging may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved urinary control and reduced complications for patients undergoing prostate cancer surgery.
How similar studies have performed: While similar robotic-assisted surgical techniques have shown promise, this specific approach is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. prostate biopsy and clinical confirmation of high-risk prostate cancer (PSA \> 20 ng/mL, Gleason score ≥ 8, or cT stage ≥ T2c) followed by robotic-assisted radical prostatectomy 2. multiparametric MRI (mpMRI) with a 3.0 T scanner for prostate or pelvic scans performed within 30 days before the operation at our center 3. Eastern Cooperative Oncology Group (ECOG) performance status score between 0 and 1 4. Complete clinical and prostate biopsy pathological data. 5. General health is good, with no infections, autoimmune diseases, hematologic disorders, or other malignancies. Exclusion Criteria: 1. Presence of surgical contraindications. 2. refusal of enhanced mpMRI imaging.
Where this trial is running
Fuzhou, Fujian
- first hospital affiliated of Fujian medical university — Fuzhou, Fujian, China (Recruiting)
Study contacts
- Study coordinator: Xu Ning, Dr.
- Email: drxun@fjmu.edu.cn
- Phone: +8613235907575
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.